[{"NetIncomeLossConverted_1_Q1_USD":-33015000.0,"NetCashProvidedByUsedInOperatingActivitiesConverted_1_Q1_USD":-49328000.0,"CommonStockSharesOutstanding_0_Q1_shares":141470075.0,"StockholdersEquity_0_Q1_USD":1069779000.0,"EarningsPerShareBasic_1_Q1_USD":-0.25,"RevenuesConverted_1_Q1_USD":38345000.0,"Assets_0_Q1_USD":1179044000.0,"CommonStockSharesConverted_0_Q1_shares":141470075.0,"Ticker":"ALLO","CIK":"1737287","name":"ALLOGENE THERAPEUTICS, INC.","OfficialName":"Allogene Therapeutics Inc. Common Stock","form":"10-Q","period":"20210331","fy":"2021.0","fp":"Q1","qtrs":"1","uom":"USD","footnote":"nan","Market Cap":"1134878416.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Biological Products (No Diagnostic Substances)","Market":"NASDAQ","SP500":"nan","filed":"20210505"}]